

# THE SELECTION AND USE OF ESSENTIAL MEDICINES

Report of the WHO Expert Committee, 2007  
(including the 15th Model List of Essential Medicines)



World Health  
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications. The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences. To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective — the attainment by all people of the highest possible level of health.

---

*The WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about six such reports, costs CHF 168.00/US\$ 151.00 (CHF 128.40/US\$ 115.00 in developing countries). For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int); order on line: <http://www.who.int/bookorders>).

*This report contains the collective views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization*

**WHO Technical Report Series**

**946**

---

# **THE SELECTION AND USE OF ESSENTIAL MEDICINES**

---

Report of the WHO Expert Committee, 2007  
(including the 15th Model List of Essential Medicines)



**World Health  
Organization**

---

WHO Library Cataloguing-in-Publication Data

WHO Expert Committee on the Selection and Use of Essential Medicines  
(15<sup>th</sup>: 2007: Geneva, Switzerland)

The selection and use of essential medicines: report of the WHO Expert Committee, 2007:  
(including the 15<sup>th</sup> model list of essential medicines).

(WHO technical report series; no. 946)

1. Essential drugs - standards. 2. Formularies - standards. 3. Drug information services  
- organization and administration. 4. Drug utilization. 5. Pharmaceutical preparations  
- classification. 6. Guidelines. I. Title. II. Title: 15<sup>th</sup> model list of essential medicines.  
III. Series.

ISBN 978 92 4 120946 5  
ISSN 0512-3054

(LC/NLM classification: QV 55)

© **World Health Organization 2007**

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications — whether for sale or for noncommercial distribution — should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

**Typeset in Switzerland  
Printed in Switzerland**

# Contents

1. Introduction	1
2. Open session	2
3. Update on current activities	4
3.1 Procedure to update and disseminate the Model List	4
3.2 Proposal for subcommittee on essential medicines for children	6
3.3 Proposal on listing fixed-dose combination products for infectious diseases	8
3.4 Report from the Advisory Committee on Safety of Medicinal Products	10
3.5 Update of dosage forms and strengths for products on the Model List	10
3.6 Rare diseases proposal	12
3.7 Procedure for updating the content of the Interagency Emergency Health Kit	13
3.8 Late agenda item on medicines for acute care	14
3.9 Report on WHO Model Formulary	14
3.10 Report on Drug Bulletin manual	15
3.11 Review of proposal regarding critically important antibiotics	15
3.12 Advice on draft resolution on rational use of medicines	16
4. Changes made in revising the Model List by section: medicines for all populations	18
4.1 Section 2: addition of prolonged-release morphine	18
4.2 Section 6.1: deletion of levamisole as anthelmintic	19
4.3 Section 6.2.1: Beta lactam: addition of cefazolin/cefalexin	20
4.4 Section 6.2.4: Antituberculosis medicines	22
4.5 Section 6.4.2: Antiretrovirals	24
4.6 New section under 6.4.3: Addition of new section and medicine ribavirin	35
4.7 Late item: antiviral medicines for pandemic influenza	35
4.8 Section 6.5.2: Antileishmaniasis: addition of paromomycin	36
4.9 Section 6.5.3: Antimalarial medicines	37
4.10 Review of Section 6.5.5: Antitrypanosomal medicines	40
4.11 Section 7: Antimigraine medicines	42
4.12 Section 8.2: Cytotoxic drugs	44
4.13 Review of section 8.4: Medicines used in palliative care	45
4.14 Section 12.6: Lipid-lowering drugs: addition of simvastatin	46
4.15 Section 18.3: Contraceptives	48
4.16 Section 19.2: Sera and immunoglobulins	52
4.17 Review of section 19.3: Vaccines	54
4.18 Section 21.1: Ophthalmological preparations – Anti-infective agents	56
4.19 Section 24: Psychotherapeutic medicines – 24.2.1: Medicines used in depressive disorders	58

5. Paediatric medicines	59
5.1 Section 5: Anticonvulsants/antiepileptics	59
5.2 Section 6.2.4: Antituberculosis medicines	62
5.3 Section 6.5.3: Antimalarial medicines	63
5.5 Section 25: Medicines acting on the respiratory tract	64
5.6 Section 27: Vitamins and minerals	65
6. Summary of recommendations – additions, changes and deletions to the Model List	66
References	70
Annex 1	
<b>Declaration of interests of Committee Members</b>	79
Annex 2	
<b>The 15<sup>th</sup> WHO Model List of Essential Medicines</b>	81
Annex 3	
<b>The Anatomical Therapeutic Chemical (ATC) classification system</b>	117
Annex 4	
<b>Alphabetical list of essential medicines (with ATC classification code numbers)</b>	138
Annex 5	
<b>Proposed procedure to update and disseminate the WHO Model List of Essential Medicines</b>	146
Annex 6	
<b>Revised procedure for updating the content of the Interagency Emergency Health Kit</b>	152

# WHO Expert Committee on the Selection and Use of Essential Medicines

Geneva, 19–23 March 2007

## Members

- Dr Lisa Bero, (Rapporteur), University of California, San Francisco, CA, USA
- Dr Noël Cranswick, Director, Clinical Pharmacology, Royal Children's Hospital, Parkville, Victoria, Australia
- Dr Rohini Fernandopulle, Senior Lecturer, Department of Pharmacology, Faculty of Medicine, University of Colombo, Sri Lanka
- Dr Anwar-ul Hassan Gilani, National Professor of Pharmacology, Department of Biological and Biomedical Sciences, Faculty of Health Sciences, The Aga Khan University, Karachi, Pakistan
- Dr Usha Gupta, Delhi Society for Promotion of Rational Use of Drugs, Delhi Government Dispensary, New Delhi, India
- Dr Abdelkader Helali, Director, Centre National de Pharmacovigilance et Matéiovigilance, Ministère de la Santé et de la Population, Alger, Algeria
- Dr Alar Irs, Deputy Director-General, State Agency of Medicines, University of Tartu, Tartu, Estonia
- Dr Youping Li, Chinese Cochrane Centre, West China Hospital, Sichuan University, Chengdu, People's Republic of China
- Dr Liliana de Lima, Executive Director, International Association for Hospice and Palliative Care, Houston, TX, USA
- Mr Dinesh Mehta, Executive Editor, British National Formulary, Royal Pharmaceutical Society of Great Britain, London, England
- Dr Marcus M. Reidenberg, (Chair), Chief, Division of Clinical Pharmacology, Weill Medical College of Cornell University, New York, NY, USA
- Dr Sri Suryawati, Director, Centre for Clinical Pharmacology and Medicine Policy Studies, Gadjah Mada University, Yogyakarta, Indonesia
- Dr Susan Walters, Lyons, ACT, Australia
- Dr Lenita Wannmacher, Department of Clinical Pharmacology, School of Medicine, University of Passo Fundo, Rio Grande do Sul, Brazil

## Temporary advisers

- Professor Hany Abdel-Aleem, Department of Obstetrics and Gynecology, Assiut University Hospital, Assiut, Egypt
- Dr Albert Figueras, Fundació Institut Català de Farmacologia, Servei de Farmacologia Clínica, Hospital Vall d'Hebron, Barcelona, Spain
- Mr Andy Gray, Department of Therapeutics and Medicines Management, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, South Africa

Dr Estrella Paje-Villar, Professor of Paediatrics and Pharmacology, Faculty of Medicine, University of Sto. Tomas, Sampaloc, Manila, Philippines

Dr Thamizhanban Pillay, Pharmaceutical Economic Evaluation, National Department of Health, Pretoria, South Africa

### **Representatives of other organizations**

*United Nations Children's Fund (UNICEF)*

Dr Hanne Bak Pedersen, UNICEF Supply Division, Copenhagen, Denmark

*United Nations Population Fund (UNFPA)*

Dr Lindsay Edouard, Senior Adviser, Reproductive Health Branch, United Nations Population Fund, New York, USA

### **Secretariat**

Dr Suzanne Hill, Scientist, Policy, Access and Rational Use (PAR)/Medicines Policy and Standards (PSM) and Secretary of the WHO Expert Committee on the Selection and Use of Essential Medicines, WHO, Geneva, Switzerland

Dr Hans V. Hogerzeil, Director, Medicines Policy and Standards (PSM), WHO, Geneva, Switzerland

Dr Clive Ondari, Coordinator, Policy, Access and Rational Use (PAR)/Medicines Policy and Standards (PSM), WHO, Geneva, Switzerland

Dr Jane Roberston, Policy, Access and Rational Use (PAR)/Medicines Policy and Standards (PSM), WHO, Geneva, Switzerland

Dr Budiono Santoso, Health Technology and Pharmaceuticals, Health Sector Development, DHS/PHA, WHO Regional Office for the Western Pacific (WPRO), Manila, Philippines

Dr Lilia Ziganshina, Policy, Access and Rational Use (PAR)/Medicines Policy and Standards (PSM), WHO, Geneva, Switzerland

Dr Howard Zucker, Assistant Director-General, Health Technology and Pharmaceuticals (HTP Cluster), WHO, Geneva, Switzerland

预览已结束，完整报告链接

<https://www.yunbaogao.cn/report/index/repo>